454 related articles for article (PubMed ID: 26677336)
1. Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Awasthi N; Schwarz RE
Onco Targets Ther; 2015; 8():3691-701. PubMed ID: 26677336
[TBL] [Abstract][Full Text] [Related]
2. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
8. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
9. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
Kutluk Cenik B; Ostapoff KT; Gerber DE; Brekken RA
Mol Cancer Ther; 2013 Jun; 12(6):992-1001. PubMed ID: 23729403
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor.
Reck M
Expert Rev Anticancer Ther; 2015 May; 15(5):579-94. PubMed ID: 25831142
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
Reck M; Mellemgaard A
Biologics; 2015; 9():47-56. PubMed ID: 26170616
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of nintedanib for advanced non-small-cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Ther Clin Risk Manag; 2015; 11():1701-6. PubMed ID: 26622180
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
16. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.
Santos ES; Gomez JE; Raez LE
Invest New Drugs; 2012 Jun; 30(3):1261-9. PubMed ID: 21350804
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
18. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila J; Carrato A; Tabernero J; Grande E
Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
[TBL] [Abstract][Full Text] [Related]
19. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.
Corrales L; Nogueira A; Passiglia F; Listi A; Caglevic C; Giallombardo M; Raez L; Santos E; Rolfo C
Front Med (Lausanne); 2017; 4():13. PubMed ID: 28293555
[TBL] [Abstract][Full Text] [Related]
20. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
